Cost-effectiveness of PET imaging in clinical oncology

Nuclear Medicine and Biology

Volumn 23, Issue 6, 1996, Pages 737-743

  Valk, Peter E ^a,b   Pounds, Thomas R ^a   Tesar, Ruth D ^a   Hopkins, Donald M ^c   Haseman, Michael K ^a,b  

^a Northern California PET Imaging Ctr   (United States)

^b Radiological Associates of Sacramento Medical Group Inc   (United States)

^c Sutter Community Hospitals   (United States)

Author keywords

cost effectiveness; oncology; PET

Indexed keywords

CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY;

EID: 0030220982     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(96)00080-7     Document Type: Conference Paper

References (23)

1. 18F]2-deoxy-2-fluoro-D-glucose PET. Radiology 187, 743-750.
2. 2. Crowe J. P., Adler L. P., Shenk R. R. and Sunshine J. L. (1994) Positron emission tomography and breast masses: Comparison with clinical, mammographic and pathological findings. Ann. Surg. Oncol. 1, 132-140.
3. 3. Dewan N. A., Gupta N. C., Redepenning L. S., Phalen J. J. and Frick M. P. (1993) Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Chest 104, 997-1002.
4. 4. Gritters L. S., Francis I. R., Zasadny K. R. and Wahl R. L. (1993) Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J. Nucl. Med. 34, 1420-1427.
5. 18F]FDG). Gynecol. Oncol. 51, 197-204.
6. 6. Ito K., Kato T., Tadokoro M., Ishiguchi T., Oshima M., Ichigaki T. and Sakuma S. (1992) Recurrent rectal cancer and scar: Differentiation with PET and MR imaging. Radiology 182, 539-552.
7. 7. Kirgan D., Guenther J., Bhattathiry M. Glass E., Hoh C., Maddahi J., Blahd W. and Morton D. (1994) The importance of whole-body PET scans in the management of metastatic malignant melanoma. Proc. Am. Soc. Clin. Oncol. 13, 396.
8. 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344, 1265-1266.
9. 18]-fluoro-2-deoxy-glucose: Correlation with CT. Radiology 190, 111-116.
10. 18F] fluorodeoxyglucose PET scanning. Radiology 188, 187-190.
11. 11. Pauker S. G. and Kassirer J. P. (1975) Therapeutic decision making: A cost-benefit analysis. N. Engl. J. Med. 293, 229-234.
12. 12. Phelps C. E. and Mushlin A. I. (1988) Focusing technology assessment using medical decision theory. Med. Decis. Making 8, 279-289.
13. 13. Pounds T. R., Valk P. E., Haseman M. K., Myers R. W. and Lutrin C. L. (1995) Whole-body PET-FDG imaging in diagnosis of recurrent colorectal cancer. J. Nucl. Med. 36, 57P.
14. 14. Pounds T. R., Valk P. E., Spitler L., Haseman M. K., Myers R. W. and Lutrin C. L. (1995) Whole-body PET-FDG imaging in diagnosis of metastatic melanoma. J. Nucl. Med. 36, 116P.
15. 18F]fluorodeoxyglucose. Ann. Thorac. Surg. 58, 698-703.
16. 16. U.S. Department of Health and Human Services (1994) DRG Guidebook. St Anthony's Press, Reston, VA.
17. 17. U.S. Department of Health and Human Services (1995) ICD-9-CM Code Book, 5th edn. St. Anthony's Press, Reston, VA.
18. 18. U.S. Department of Health and Human Services (1995) Medicare Participating Provider Program - California Physician Fee Schedule (Area 4). U.S. Department of Health and Human Services.
19. 19. Strauss L. G., Clorius J. H., Schlag P., Lehner B., Kimmig B., Engenhart R., Marin-Grez M., Heius F., Oberdorfer F. and Schmidlin P. (1989) Recurrence of colorectal tumors: PET evaluation. Radiology 170, 392-332.
20. 20. Valk P. E., Pounds T. R., Hopkins D. M., Haseman M. K., Hofer G. A., Greiss H. B., Myers R. W. and Lutin C. L. (1995) Staging non-small-cell lung cancer by whole-body positron emission tomographic imaging. Ann. Thorac. Surg. 60, 1573-1582.
21. 21. Valk P.E., Pounds T. R., Wolkov H. B., Leibenhaut M., Haseman M. K., Myers R. W. and Lutrin C. L. (1995) PET-FDG whole-body imaging in staging Hodgkin's disease: Comparison to conventional imaging. J. Nucl. Med. 36, 199P.
22. 18]-fluoro-2-deoxy-glucose. Radiology 179, 765-770.
23. 23. Wahl R. L., Quint L. E., Greenbough R. L., Meyer C. R., White R. L. and Orringer M. B. (1994) Staging of mediastinal non-small-cell lung cancer with FDG PET, CT and fusion images: preliminary prospective evaluation. Radiology 191, 371-377.